JYANT Technologies

JYANT Technologies is a precision medicine biotechnology company dedicated to developing transformative therapies for neurodevelopmental and neuropsychiatric disorders. The company leverages a proprietary platform that integrates human genetics, clinical data, and advanced analytics to identify patient subpopulations most likely to respond to specific therapeutic interventions. Their lead programs focus on conditions such as Fragile X Syndrome and Autism Spectrum Disorder, utilizing a "precision-first" approach to clinical development. By targeting the underlying molecular drivers of these conditions, JYANT aims to overcome the historical challenges of patient heterogeneity in CNS drug development. The company is led by experienced neuroscience drug developers and is headquartered in the San Francisco Bay Area.